Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer
Written by
Cancer Network
Published
0
comments
0
min
Data from the phase 1/2 RAINFOL-01 trial support the agency’s regulatory decision on rinatabart sesutecan in advanced endometrial cancer.